T1	Participants 1015 1075	Twenty-one registered patients with stage III gastric cancer
T2	Participants 1172 1185	control group
T3	Participants 1401 1423	PSK and control groups
T4	Participants 1136 1145	PSK group
T5	Participants 1498 1507	PSK group
T6	Participants 1524 1531	control
T7	Participants 1555 1563	patients
T8	Participants 1579 1587	patients
T9	Participants 1919 1947	group treated with PSK + UFT
T10	Participants 1968 1986	CD57-high patients
T11	Participants 2011 2028	CD57-low patients
